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A major unmet clinical need is a universal method for 
subcellular targeting of bioactive molecules to  lysosomes. 
Delivery to this organelle enables either degradation of 
oncogenic receptors that are overexpressed in cancers, or 
release of prodrugs from antibody–drug conjugates. Here, 
we describe a general method that uses receptor crosslink-
ing to trigger endocytosis and subsequently redirect traf-
ﬁcking of receptor:cargo complexes from their expected 
route, to lysosomes. By incubation of plasma membrane 
receptors with biotinylated cargo and subsequent addi-
tion of streptavidin to crosslink receptor:cargo–biotin 
complexes, we achieved rapid and selective lysosomal 
targeting of transferrin, an anti-MHC class I antibody, and 
the clinically approved anti-Her2 antibody trastuzumab. 
These three protein ligands each target a receptor with a 
distinct cellular function and intracellular trafﬁcking pro-
ﬁle. Importantly, we conﬁrmed that crosslinking of trastu-
zumab increased lysosomal degradation of its cognate 
oncogenic receptor Her2 in breast cancer cell lines SKBR3 
and BT474. These data suggest that crosslinking could be 
exploited for a wide range of target receptors, for navigat-
ing therapeutics through the endolysosomal pathway, for 
signiﬁcant therapeutic beneﬁt.
Received 29 May 2015; accepted 1 September 2015; advance online  
publication 27 October 2015. doi:10.1038/mt.2015.178
INTRODUCTION
For many therapeutics, delivery to lysosomes must be carefully con-
trolled, either to minimize or to maximize proteolytic degradation 
of the therapeutic, and/or its target. For example, antibodies that 
bind to transferrin receptor (TfR) for delivery across the blood–
brain barrier (BBB) must avoid lysosomal degradation.1–3 On the 
other hand, antibodies that target oncogenic receptors are often 
targeted toward lysosomes in order to provide therapeutic benefits, 
either by depleting the growth-inducing oncogenic receptors or by 
unleashing toxic drugs from antibody–drug conjugates (ADCs).4
In general, the first stage in directing ADCs to these environ-
ments conceptually involves taking the ADC to a cell and then 
exploiting the antibodies’ specificity to bind a receptor that is 
selectively expressed on the diseased cell of choice.4 However, 
specific activity of the ADC within the target cell requires not 
just cell entry at a particular portal, but that the ADC:receptor 
complex traffics to lysosomes,5 where the cytotoxic drug can be 
released into the cytosol and access its target. This is either by 
degradation of the antibody or by cleavage of an antibody–drug 
linker.6–8 Inefficient lysosomal delivery, which in fact is evident for 
many ADCs,9,10 is expected to limit the amount of cytotoxic drug 
released inside tumor cells and result in suboptimal potency.5 To 
date, the only ADCs that have demonstrated sufficient efficacy to 
gain and retain clinical approval are trastuzumab–emtansine and 
brentuximab–vedotin.11
In order to evaluate delivery of exogenous proteins to lysosomes 
within the context of ADCs, we sought to exploit the enhanced 
trafficking to lysosomes that many receptors perform when clus-
tered or crosslinked into “supramultivalent”  interactions. This 
enhanced and sometimes aberrant lysosomal delivery has been 
observed for many receptors,12 including rabies G protein,13 ErbB 
family receptors such as epidermal growth factor receptor,14,15 
acetylcholine  receptors,16,17 and FcRn receptors.18 These findings 
were demonstrated in a range of cell types, including hamster 
kidney,12 mouse neuroblastoma,13 human kidney,14 human epi-
dermal,15 rat muscle,16 Xenopus  muscle,17 and human endothelial 
cells.18 Furthermore, crosslinking was induced in these reports by 
a range of methods, including streptavidin (SA),12,17 bivalent anti-
bodies,13,16,18 natural ligands,14,18 and multivalent designed ankyrin 
repeat proteins (DARPins).15 In the case of CD20 receptors, anti-
body-mediated crosslinking has been utilized to modify cell sig-
naling and drive apoptosis in myeloma cells.19
Surprisingly, despite the need for methods to deliver therapeu-
tic ligands to lysosomes, the possibility of exploiting crosslinking 
for enhancing the uptake and subcellular targeting of therapeutic 
vectors and/or their cognate receptors has not been widely stud-
ied. Here, we demonstrate that we can increase delivery of three 
exogenously administered proteins, targeting distinct receptors, 
to lysosomes by formation of biotin: SA complexes at the plasma 
membrane. To do this, we add exogenous biotinylated antibodies or 
biotinylated protein ligands to cells and optionally induce complex 
formation with SA. By generating proteins that are dual-labeled 
with biotin and fluorophores, and imaging these by live cell confo-
cal microscopy, we observe major differences in intracellular traffic 
of uncomplexed versus complexed proteins. As models to dem-
onstrate this phenomenon, we selected three exogenous protein 
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ligands that either do not traffic to lysosomes in their uncomplexed 
state (transferrin (Tf)) or do so minimally: the anti(MHC I) anti-
body W6/32 and the anti-Her2 antibody trastuzumab (TRz).
The trafficking route of Tf has been extensively character-
ized: It first binds to the TfR, and both then internalize together 
via clathrin-mediated endocytosis,20 which requires the AP2-coat 
complex.21 Following release of bound iron, Tf:TfR is recycled to 
the plasma membrane, where the Tf is then released.22 The ability 
of Tf to recycle has been exploited for delivery of various therapeu-
tics (drugs, genes, proteins) across biological barriers including the 
BBB.23,24 TfR-mediated transport across the BBB occurs via trans-
cytosis, in which TfR:cargo complexes are endocytosed at the api-
cal face of endothelial cells and subsequently recycled at the distal 
basolateral surface. In addition to Tf, antibodies that bind TfR have 
been investigated for their ability to cross this barrier, but these 
efforts have been hindered by trafficking of TfR to  lysosomes.1–3 
An understanding of TfR:cargo trafficking may therefore enable 
us to design improved vectors for delivery of therapeutics into 
the brain via a transcytosis route that avoids lysosomal delivery. 
Other work on TfR trafficking has shown that local clustering of 
TfR increases the rate of endocytosis25 and that lysosomal delivery 
can be induced using a monoclonal bivalent anti-TfR antibody.26
The W6/32 antibody targets the MHC class I complex, which 
localizes predominantly to the plasma membrane.27 In contrast to 
Tf, endocytosis of the anti(MHC I) antibody W6/32 is clathrin 
independent.28–30 A “quality control” mechanism is proposed to 
exist,31 in which loss of β2 microglobulin from the MHC class I 
complex results in clustering of the remaining MHC class I heavy 
chain (which contains the epitope for W6/32)32 and its subsequent 
delivery to lysosomes.33 It has further been shown that induced 
crosslinking of the MHC class I complex causes signaling,34–37 
which may serve as an indicator for the integrity of the MHC class 
I complex. Determining the endocytic fate of complexed W6/32 is 
thus a crucial test of the MHC class I quality control hypothesis.
TRz is a humanized monoclonal antibody that binds to Her2 and 
is used clinically either as an unconjugated antibody (“Herceptin”)38 
or as the ADC TRz-emtansine (“Kadcyla”).39 Her2 is overexpressed 
in 15–20% of diagnosed breast cancers,40,41 where it forms onco-
genic signaling dimers with other, ligand activated, receptors from 
the ErbB family. Her2 is considered to be difficult to deliver to lyso-
somes, firstly because it is resistant to internalization and secondly 
because the majority of endocytosed receptor recycles back to the 
plasma membrane.38,42 Furthermore, patients treated clinically with 
TRz routinely develop resistance to treatment, which prevents Her2 
degradation.43,44 One promising method for overcoming resistance 
to internalization is to induce Her2 clustering,45–50 yet it remains to 
be determined whether SA can be used to deliver Her2:antibody 
complexes to lysosomes for degradation.
Here, we report that targeting cells with biotinylated ligands 
and subsequent addition of SA efficiently targets Tf, W6/32, and 
TRz to lysosomes and also enhances the degradation of Her2 in 
breast cancer cell lines that overexpress this receptor.
RESULTS
We initially investigated whether formation of biotin:SA com-
plexes at the plasma membrane affects the endocytosis and traffic 
of the iron carrying protein Tf. Normally this protein undergoes 
endocytosis via the TfR into clathrin-coated vesicles, is trafficked 
to recycling endosomes, and then recycled back to the plasma 
membrane, thus avoiding delivery to lysosomes.22,51
Dual-labeled Tf (Tf-Bi-647) was generated by reaction of 
Tf-biotin (Tf-Bi) with NHS-Alexa647 (see Supplementary 
Figure  S2 for physical characterization and Supplementary 
Tables S1 and S2 for quantification). Due to the presence of 
multiple biotins per Tf-Bi-647 and multiple biotin-binding sites 
per SA, co-incubation of Tf-Bi-647 and SA to cells could result 
in formation of Tf-Bi-647:SA aggregates in solution.52 This was 
avoided by using a sequential addition protocol53 (Figure 1) that 
involved incubating HeLa cells with Tf-Bi-647, washing to remove 
unbound Tf-Bi-647, and then addition of SA. In order to prevent 
Tf-Bi-647 endocytosis before the addition of SA, incubations with 
Tf conjugates, SA, and SA conjugates were performed on ice.
Initially, it was important to investigate whether biotinylation 
of Tf had any effect on its recycling, and for this, we simultaneously 
compared trafficking of biotinylated (Tf-Bi-647) and unbiotinyl-
ated (Tf-488) forms of this protein. HeLa cells were co-incubated 
with both forms on ice and then incubated at 37 °C for 60 minutes, 
with imaging of the two probes at the indicated time points by 
live cell confocal microscopy. Representative confocal microscopy 
images (Supplementary Figure S3) show that Tf-488 and Tf-Bi-647 
are recycled. In order to quantify the rate of recycling, we cal-
culated the average intensity per pixel in the fluorescent vesicle 
regions using a threshold and background subtraction method as 
described in Supplementary Method 1 and Figure S1. We then 
defined the “normalized intensity” as the intensity relative to the 
mean fluorescence intensity at 10 minutes when the majority of 
Tf has been internalized into early and recycling endosomes. This 
dataset (n = 3) is quantified in Figure 2a which demonstrates that 
Tf-Bi-647 and Tf-488 are recycled out of cells at very similar rates, 
thus biotinylation does not affect the rate of Tf recycling.
In the same experiment, in order to evaluate lysosomal deliv-
ery of exogenously applied fluorescently labeled proteins, cells 
were pulse-chased with the fluid-phase endocytosis probe Dex-
546 (see Materials and Methods) to specifically label lysosomes.54 
Representative images demonstrate that Tf-488 and Tf-Bi-647 
colocalize with each other, but not with Dex-546 labeled lyso-
somes (Supplementary Figure S4). To quantify this, colocaliza-
tion between all pairs of fluorescent labels are represented using 
Pearson’s coefficient (PC), which is calculated as the r value for 
the correlation of pixel intensities between corresponding pixels 
of two images. As expected, Tf-Bi-647 and Tf-488 colocalized 
together (mean PC of 0.65, Figure 2b, green line), and neither 
of these proteins colocalized strongly (PC < 0.35) with pulse-
chased Dex-546 (Figure 2b). In summary, these results dem-
onstrate that biotinylation of Tf did not perturb its endocytic 
traffic and Tf-Bi-647 is recycled rather than being delivered to 
lysosomes.
We then evaluated the capacity of SA-488 to bind Tf-Bi-647 
on the plasma membrane. HeLa cells were labeled by sequential 
addition of Tf-Bi-647 and then fluorescently labeled SA (SA-488) 
at 0 °C. Labeled cells were then incubated at 37 °C for 6 hours with 
regular imaging of the two probes by live cell confocal microscopy. 
Quantitative analyses of these fluorescence images (Figure 2c,d) 
show an increase in normalized intensity for Tf-Bi-647 and 
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SA-488 between 10 and 120 minutes (Figure 2c). This increase 
in the average intensity per pixel in the fluorescent regions above 
threshold suggests that the signal is clustered into fewer organ-
elles. Strong colocalization of Tf-Bi-647 and SA-488 (PC > 0.8, 
Figure 2d, green line) suggests that they remained tightly associ-
ated for the duration of the experiment (6 hours). There was a 
clear time-dependent increase in colocalization of Dex-546 with 
both Tf-Bi-647 and SA-488 to a PC of ~0.9 (Figure 2d), demon-
strating that Tf-Bi-647:SA-488 complexes did not effectively recy-
cle and were trafficked to lysosomes. Representative images after 
10 and 360 minutes of incubation for this experiment are shown 
in Figure 2g,h, which highlight the increased colocalization of 
Tf-Bi-647:SA complexes with Dex-546 in lysosomes between 
these time points.
We simultaneously compared lysosomal delivery of unbioti-
nylated Tf-488 and biotinylated Tf-Bi-647 in the presence of SA 
(Figure 2e,f). HeLa cells were first co-incubated at 0 °C with equal 
concentrations Tf-488 and Tf-Bi-647, washed, and then incubated 
with unlabeled SA. Unbiotinylated Tf-488 was rapidly recycled 
from the cell (Figure 2e, blue line), whereas Tf-Bi-647:SA com-
plexes were retained within the cell (Figure 2e, red line) and 
trafficked to lysosomes (final PC > 0.8, Figure 2f). In Figure 2f, 
colocalization values are not shown for Tf-488 after 60 minutes, 
due to the fact that the majority of it has been recycled from 
the cell. Representative images of Tf-Bi-647(:SA) are shown in 
Supplementary Figure S3 (right-hand column), which highlight 
that addition of SA inhibits recycling of Tf-Bi-647.
We then investigated whether the Tf-Bi-647:SA complexes 
formed at the plasma membrane are internalized, like Tf, via the 
canonical clathrin-mediated endocytosis route. To test this, an 
adapter protein subunit AP2μ2 (which is essential for clathrin-
mediated endocytosis) was depleted in HeLa cells using siRNA.55 
Three AP2μ2 targeting sequences were tested, and western blot-
ting demonstrated that all three effectively depleted the protein 
(Supplementary Figure S5a). We then initially tested whether 
depleting AP2μ2 from cells selectively influenced Tf uptake 
over BSA-488, which is proposed to enter via a different route.56 
Co-incubation of control and AP2μ2-siRNA–treated cells with 
Tf-647 and BSA-488 demonstrated that depletion of AP2μ2 caused 
retention of Tf-647 on the plasma membrane (Supplementary 
Figure S5b), but no visual effects were noted on the localization 
and uptake of BSA-488 between the two cell treatments.
Tf-Bi-647:SA complexes were then generated on the surface 
of control and AP2μ2-depleted HeLa cells by sequential addition 
of Tf-Bi-647 and SA at 0 °C. Cells were then incubated at 37 °C 
for 10 or 60 minutes to permit internalization of the complexes. 
For removal of membrane-bound Tf-Bi-647:SA complexes, the 
cells were then acid washed at pH 4.5 prior to visualization by 
live cell confocal microscopy. Comparison of control cells (GFP-
siRNA, Figure 3a) with AP2μ2-siRNA cells (Figure 3b) reveals 
that depletion of AP2μ2 results in retention of Tf-Bi-647:SA at the 
plasma membrane. This demonstrates that these complexes are, 
like Tf alone, endocytosed by clathrin-mediated endocytosis.
We additionally observed that after the acid wash procedure, 
Tf-Bi-647:SA complexes were still retained on the plasma mem-
brane (Figure 3c), whereas Tf-Bi-647 alone was almost completely 
removed (Figure 3d). This suggests that Tf-Bi-647:SA complexes 
are refractory to acid washing and bound more tightly to cells due 
to increased avidity.
In view of the dramatic mislocalization of Tf caused by 
SA, we investigated whether a similar effect was observed for a 
very different ligand. For this, we selected the W6/32 antibody 
against the MHC class I receptor, which has been documented 
to enter cells via a clathrin-independent endocytic pathway.28–30 A 
Figure 1 Formation of protein–Bi:SA complexes by sequential incubation. (a) Exogenous biotinylated protein is added to cells. (b) Excess 
unbound protein is removed by washing. (c) Streptavidin is added to cells, which has the capacity to cluster receptors by formation of extended cross-
links between receptor:ligand–biotin complexes. (d) Excess streptavidin is removed by washing prior to incubation at 37 °C. Cells are subsequently 
imaged by live cell confocal microscopy to monitor location of the complex in endolysosomal organelles.
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Figure 2 Tf-Bi-647:SA complexes trafﬁc to lysosomes. HeLa cells were pulse-chased with Dex-546 to label lysosomes, and then incubated for 30 
minutes in serum-free media. Cells were then placed on ice and incubated with the following solutions (15 min per incubation step, with PBS washes 
between each incubation): (a and b) co-incubation of 10 μg/ml Tf-Bi-647 and 10 μg/ml Tf-488, (c, d, g, and h) 10 μg/ml Tf-Bi-647, followed by 
incubation with 1 μg/ml SA-488. (e and f) co-incubation of 10 μg/ml Tf-Bi-647 and 10 μg/ml Tf-488, followed by incubation with 1 μg/ml unlabeled 
SA. After incubation on ice, cells were incubated at 37 °C in complete medium and imaged as live cells at the denoted time points. Normalized 
intensity (a, c, and e) represents the average ﬂuorescence intensity per pixel above the threshold and after background subtraction (see 
Supplementary Method 1). Pearson’s coefﬁcients in b, d, and f are a measure of how closely the ﬂuorescent regions of two images overlap. Error 
bars represent SD between mean values for three independent experiments. Representative single slice confocal microscopy images of Tf-Bi-647:SA 
complexes are shown after (g) 10 minutes or (h) 360 minutes. Arrowheads denote vesicles with Tf-Bi-647:SA-488 complexes, and arrows denote 
vesicles containing Tf-Bi-647, SA-488, and Dex-546. Scale bars of top rows (g and h) = 10 μm; bars of bottom rows (g and h) = 5 μm.
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biotinylated anti-MHC class I antibody was further labeled with 
NHS-Alexa488 to generate Bi-anti(MHC I)-488 (Supplementary 
Figure S2 for physical characterization, Supplementary Tables S1 
and S2 for quantification). HeLa cells with lysosomes preloaded 
with Dex-546 were incubated at 37 °C with Bi-anti(MHC I)-488 
for 30 minutes, and then with 0 or 1 μg/ml unlabeled SA for 30 
minutes. After treatment, cells were incubated at 37 °C for 
4  hours, and then imaged by live cell confocal microscopy. For 
visual inspection, the contrast of each image was adjusted post-
acquisition, to evaluate how the antibody is distributed through-
out the cell (Figure 4a). In the absence of SA, there was extensive 
plasma membrane labeling, but a small fraction of the antibody 
had internalized into vesicles (indicated by arrowheads, top row). 
None of these internal structures were found to colocalize with 
lysosomal Dex-546. After 4 hours, plasma membrane labeling was 
still clearly evident, and some of the punctate structures were now 
located in lysosomes. Addition of SA gave a very different profile: 
Bi-anti(MHC I)-488 was localized entirely in punctate structures 
after 30 minutes, and after 4 hours, extensive colocalization was 
observed between the antibody and Dex-546. By examination of 
the wider fields of view for these images (Supplementary Figure 
S6), a complete lack of diffuse plasma membrane staining is evi-
dent for all cells treated with SA after only 30 minutes.
When the unprocessed images from these experiments were 
quantified, the results show that addition of SA results in significantly 
increased normalized intensity of Bi-anti(MHC I)-488 fluorescence 
within cells (Figure 4b; P < 0.001) at 240 minutes. From this, it was 
hypothesized that SA may increase the amount of Bi-anti(MHC 
I)-488 delivered to lysosomes. As PC colocalization values do 
not take total intensity into account, this hypothesis was tested 
by a different approach. The total amount of Bi-anti(MHC I)-488 
in lysosomes was calculated by simultaneous imaging of 
 Dex-546-labeled lysosomes and Bi-anti(MHC I)-488, then calcu-
lating the average fluorescence intensity of Bi-anti(MHC I)-488 in 
the regions that overlap with Dex-546 fluorescence (Figure 4c). SA 
caused a significantly increased delivery of Bi-anti(MHC I)-488 
to lysosomes (P < 0.05) at 240 minutes. This increase in lyso-
somal delivery may be due to enhanced endocytosis of Bi-anti 
(MHC I)-488:SA complexes over Bi-anti(MHC I)-488 alone and/or 
an inhibition of its recycling.
The humanized monoclonal antibody TRz targets Her2, an 
oncogenic receptor tyrosine kinase that is overexpressed in a sig-
nificant number of breast cancer patients. Based on our results 
on complexation of Tf and MHC class I with SA, we investigated 
whether complexation of biotinylated TRz with SA could enhance 
delivery of this antibody to lysosomes and if this could in turn 
degrade the Her2 receptor.
We generated TRz-Bi-647 by reaction of TRz with NHS-Alexa647 
and NHS-biotin, and for an unbiotinylated control, we gen-
erated TRz-488 by reaction of TRz with NHS-Alexa488 (see 
Supplementary Figure S2 for physical characterization and 
Supplementary Table S1 and S2 for quantification). The speci-
ficity of TRz-Bi-647 for Her2-expressing cells was confirmed 
in Supplementary Figure S7, which shows no association of 
TRz-Bi-647 with HeLa cells (which do not express Her2) and 
extensive binding of TRz-Bi-647 to the Her2-expressing cell 
lines SKBR3 and BT474 (ref. 38). As for the previous experi-
ments, the lysosomes of these cells were labeled by pulse- 
chasing with  Dex-546. Antibody trafficking was then evaluated 
by co- incubation with TRz-488 and TRz-Bi-647 for 30 minutes, 
followed by addition of 0 or 1 μg/ml SA prior to washing and 
incubating the cells for a further 7 hours at 37 °C. Live cell confo-
cal microscopy analysis was performed at the end of this incu-
bation period. For display of TRz-Bi-647 images only, contrast 
settings were adjusted for each image post-acquisition, so that the 
distribution of fluorescence can be seen both for low-intensity 
and for high-intensity images. For both fluorescent TRz variants, 
delivery to lysosomes was observed through colocalization with 
Dex-546. Comparative analysis showed that in both cells lines, 
in the presence or absence of SA, the localization and intensity 
of TRz-488 was unchanged, and the antibody was located both 
on the plasma membrane and in intracellular vesicles (Figure 5a 
left-hand column, wider views in Supplementary Figure S8 
left-hand column). However, in both cell lines, addition of SA 
caused TRz-Bi-647 to redistribute from the plasma membrane 
to vesicular structures (Figure 5a second column, wider views in 
Supplementary Figure S8 second column). The data therefore 
indicate that SA:biotin complexation selectively increased the 
total amount of TRz-Bi-647 that was delivered to lysosomes within 
this 7-hour period. This hypothesis was tested quantitatively as 
Figure 3 Endocytosis of Tf-Bi-647:SA complexes is inhibited in AP2μ2-depleted cells. HeLa cells were mock-treated with anti-GFP siRNA or treated 
with anti-AP2μ2 siRNA (see Materials and Methods). Cells were incubated at 0 °C with 20 μg/ml Tf-Bi-647 for 15 minutes, washed, then incubated 
at 0 °C with 1 μg/ml SA for 15 minutes. After washing, cells were incubated at 37 °C for the indicated time. All cells were acid washed (see Materials 
and Methods) immediately prior to imaging of live cells by confocal microscopy. Representative single slice images are shown. Bar = 10 μm (a and 
b) or 30 μm (c and d).
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described for Bi-anti(MHC I)-488, by using Dex-546 channel 
images to determine lysosomal regions, and then determin-
ing the total TRz intensity in these regions (Figure  5b,c). This 
demonstrated that SA significantly increased delivery of biotinyl-
ated TRz-Bi-647 to lysosomes by 145% in BT474 cells and 175% 
in SKBR3 cells. In contrast, lysosomal delivery of unbiotinylated 
TRz-488 was not significantly altered by addition of SA. As a 
further internal control, changes in the intensity of TRz-488 and 
TRz-Bi-647 in lysosomes were calculated from the same set of 
three-channel (488/546/647 nm) images.
As TRz-Bi-647:SA enhanced lysosomal delivery in BT474 and 
SKBR3 cells, we investigated whether this caused increased degra-
dation of Her2 and a concomitant reduction in total Her2 levels. 
For this, we lysed both these cell types at the end of the TRz-Bi-647 
+/- SA incubation period and detected Her2 by western blotting 
(Figure 6a). As has previously been reported for unconjugated 
TRz,57–59 TRz-Bi-647 alone caused a decrease in Her2 levels that 
was decreased further in cells treated with both TRz-Bi-647 and 
SA. Quantitative analysis of this data (Figure  6b,c) reveals that 
treatment with TRz-Bi-647:SA complexes caused a significant 
decrease in Her2 levels (to 34% in BT474 cells, 66% in SKBR3 
cells) relative to treatments with TRz-Bi-647 alone. In order to 
evaluate the duration of Her2 depletion, we used TRz-488 as a 
marker and confocal microscopy, to measure the amount of Her2 
at the plasma membrane of SKBR3 and BT474 cells at various 
time intervals after the addition of SA to induce crosslinking and 
depletion. The images and quantification of the data are shown 
in Supplementary Figure S9. These demonstrate that plasma 
membrane Her2 levels had recovered to those of untreated cells 
48 hours after crosslinking-induced depletion, consistent with a 
previous in vivo study.45
DISCUSSION
In this study, we have demonstrated for three distinct protein 
ligands that formation of receptor:[protein ligand]:SA complexes 
drives internalization and endocytic trafficking to lysosomes. 
We propose that this is a common response to receptor cross-
linking and a mechanism with wide-ranging implications espe-
cially within the field of biomolecular targeting and delivery of 
biotherapeutics.
We provide evidence that SA crosslinks multiple biotinylated 
ligands on the plasma membrane and that this has a significant 
influence on the way they are processed by the cell within the 
endolysosomal system. The fact that membrane-bound Tf-Bi-647: 
SA complexes are resistant to acid washing suggests that a net-
work of Tf ligands may be formed through SA crosslinking at 
the plasma membrane. A multivalent network is likely to have 
increased avidity for TfRs, and this crosslinking model is consis-
tent with multiple reports of membrane receptors that traffic to 
lysosomes when crosslinked.12–18,60–62 Here, we propose that cross-
linking of exogenous proteins on the cell membrane could be 
used as a general strategy for enhancing delivery of therapeutics 
to lysosomes.
Although evidence for crosslinking is provided, the extent of 
complex formation is unclear. The dependence of Tf-Bi-647:SA 
uptake on AP2μ2 suggests that crosslinked Tf still requires the 
clathrin machinery to mediate its endocytosis. Clathrin-coated 
vesicles are normally 60–120 nm in diameter,63 which suggests 
that crosslinked Tf does not form clusters larger than this. Further 
electron microscopy or single-molecule total-internal reflection 
Figure 4 SA induces delivery of Bi-anti(MHC I)-488 to lysosomes. HeLa 
cells were pulse-chased with Dex-546 to label lysosomes, then labeled 
sequentially with Bi-anti(MHC I)-488, followed by 0 or 1 μg/ml SA. 
Cells were washed and then incubated at 37 °C for 240 minutes, with 
live cells imaged at the denoted time points by confocal microscopy. Five 
or more images were taken at each time point shown. (a) Representative 
single slice confocal images of Bi-anti(MHC I)-488 and Dex-546, ± SA, 
at 30-minute and 4-hour time points. Note that intensities in the left 
column have been enhanced postacquisition and so cannot be directly 
compared. Arrowheads denote non-colocalized vesicles and arrows 
denote colocalized vesicles. Bar = 5 μm. (b) Normalized intensity analy-
sis of raw Bi-anti(MHC I)-488 images in the presence and absence of SA. 
All values are normalized relative to the intensity of Bi-anti(MHC I)-488 
without SA at 240 minutes. (c) Bi-anti(MHC I)-488 intensity in lyso-
somes was calculated as total 488 ﬂuorescence intensity in Dex-546-
labeled regions, with corresponding background ﬂuorescence intensity 
subtracted (see Supplementary Method 2). All values are normal-
ized relative to the intensity of Bi-anti(MHC I)-488(:SA) at 240 minutes. 
Error bars represent SD between mean normalized values of three inde-
pendent experiments. P values were calculated using one-tailed paired 
Student’s t-test. *P < 0.05, **P < 0.01.
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fluorescence data will be required to determine the size and distri-
bution of the complexes formed at the plasma membrane and to 
further characterize early and late endocytic events.
The data provided in this study add further evidence to a hypoth-
esis that endocytosis and lysosomal delivery are common responses 
to clustering of receptors and that these are independent of the inter-
nalization mechanism. The MHC class I receptor has been shown 
to enter cells via a clathrin-independent route involving the small 
GTPase Arf6 (refs. 28–30). These studies showed that once inter-
nalized, the same W6/32 antibody is delivered to late endosomes 
or recycled. Here, we show that biotinylation of this antibody and 
addition of SA enhanced delivery of the antibody:receptor complex 
to lysosomes. This supports the previously stated hypothesis that 
clustered MHC class I molecules are targeted for degradation as 
part of a quality control mechanism that monitors the integrity of 
[MHC class I]:[β2 microglobulin] complexes.31
Figure 5 SA selectively increases delivery of TRz-Bi-647 to lysosomes. Dex-546 loaded SKBR3 and BT474 cells were co-incubated at 37 °C with 
TRz-488 and TRz-Bi-647, then with 0 or 1 μg/ml SA prior to incubation at 37 °C for 7 hours. Wash steps were included between each incubation. 
Single slice confocal microscopy images of the three ﬂuorophores in live cells were then acquired. (a) Representative ﬂuorescence microscopy 
images; arrows denote colocalization of Dex-546 with TRz-488. Contrast settings were automatically adjusted individually for each image. 
Bar = 5 μm. (b) TRz-488 or (c) TRz-Bi-647 intensity in lysosomes was calculated as total 488/647 ﬂuorescence intensity in Dex-546-labeled 
regions, with corresponding background ﬂuorescence intensity subtracted (see Supplementary Method 2). All values are normalized to the 
corresponding -SA condition. Bars represent SD between mean normalized values of three independent experiments. P values were calculated 
using one-tailed paired Student’s t-test.
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The disruption of recycling presented here may have important 
implications for transcytosis of therapeutic cargo across biological 
barriers. Within this field, a great deal of investment has focused 
on exploiting Tf and the TfR for delivery across the BBB.23,24 Our 
observations raise the possibility that current attempts to deliver 
drugs across the BBB using multivalent systems are compromised 
by trafficking to lysosomes, thus significantly reducing the frac-
tion that is transcytosed to the brain parenchyma. It has been 
reported that transcytosis of anti-TfR antibodies from the api-
cal to the basolateral component of the BBB may be enhanced by 
using antibodies with low receptor affinities1 or reduced valency 
to the TfR.2,3 In both cases, enhanced transcytosis may be caused 
by reduced receptor crosslinking.
Crosslinking could be a valuable strategy for improving deliv-
ery of ADCs to lysosomes. In order to optimize the proof-of-prin-
ciple strategy described in this paper for therapeutic purposes, a 
range of improvements can be considered. For example, immuno-
genicity could be minimized by using less immunogenic variants 
of SA.64 Alternatively, crosslinking could be achieved by adminis-
tration of multiple antibodies that bind to different epitopes of the 
same receptor.46–48 This is the likely mechanism underpinning the 
MARIANNE trial,65 in which the anti-Her2 ADC Kadcyla is dosed 
simultaneously with Pertuzumab, a second anti-Her2 antibody 
that binds a nonoverlapping epitope to that of Kadcyla.66 Based 
on our observations, it is expected that simultaneous addition of 
these two antibodies will induce synergistic crosslinking of Her2 
receptors, resulting in lysosomal delivery of Kadcyla and release of 
its cytotoxic payload. It is likely that many potential ADCs under-
perform due to the fact that the receptor:ADC complex does not 
internalize efficiently. Furthermore, complexes that do internalize 
may recycle back to the plasma membrane rather than traffic to 
lysosomes, which is the target organelle for optimal drug release.
Although TRz drives downregulation of Her2 in vitro,57–59 TRz 
alone is insufficient to reduce Her2 levels in vivo, because tumors 
develop resistance to this treatment.43 We demonstrate for the first 
time that a Bi:SA crosslinking strategy causes a greater reduction 
in Her2 levels than treatment with TRz-Bi-647 alone. Further work 
will be required to determine if this is sufficient to overcome resis-
tance to Her2 degradation in vivo. In support of this hypothesis, a 
previous report showed that a similar TRz-Bi:SA system induced 
endocytosis of the antibody in vitro and in vivo.45 Our results fur-
ther strengthen this work by demonstrating both lysosomal deliv-
ery of TRz-Bi:SA complexes and degradation of the receptor.
An established method for drug delivery is to package drugs 
into nanoparticles that are coated with ligands, in order to 
enable selective binding to a target receptor and thus the target 
cell.67 Based on the data in this paper, we predict that the pres-
ence of multiple receptor-binding ligands on the surface of a 
nanoparticle is likely to induce receptor crosslinking, which 
may result in enhanced endocytosis and lysosomal delivery of 
nanoparticle:receptor complexes. Careful consideration should 
therefore be made when designing the number of receptor bind-
ing ligands on a nanoparticulate system.
The strategy described herein could be applied to a range of onco-
genic receptors. Our data indicate that crosslinking of receptors using 
SA has broad potential for cancer therapy, by enabling improved sub-
cellular targeting of ADCs and by driving degradation of oncogenic 
receptors. It remains to be determined how ubiquitous this response 
Figure 6 Delivery of TRz-Bi-647 to lysosomes downregulates total Her2 levels. SKBR3 and BT474 cells were incubated sequentially for 30 minutes 
at 37 °C with 0 (untreated) or 50 nmol/l TRz-Bi-647, then for 30 minutes at 37 °C with 0 or 1 μg/ml SA, followed by incubation at 37 °C for 7 hours. 
Wash steps were included between each incubation. Cell lysates were harvested and probed for total Her2 and β-actin levels by western blotting and 
chemiluminescence detection. Incubations and analysis were repeated in duplicate on three separate cell passages. (a) Representative immunoblot-
ting from a single experiment performed in duplicate. (b and c) Analysis of Her2 intensities relative to β-actin in (b) BT474 cells (c) SKBR3 cells relative 
to a β-actin control. Bars represent SD, and P values represent variation between the mean of three independent experiments. *P < 0.05, **P < 0.01.
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is among plasma membrane proteins, but the data provide strong 
pointers toward how designed ligand:receptor clusters could be uti-
lized to alter cell trafficking pathways for therapeutic gain. In turn, by 
specifically avoiding receptor clustering, it may be possible to direct 
biomolecules away from degradative pathways, leading to pathway 
switching by design for new pharmaceutical entities.
MATERIALS AND METHODS
Materials. Transferrin-Alexa488 (Tf-488), transferrin-Alexa647 
 (Tf-647), 10 kDa dextran-Alexa546 (Dex-546), SA-Alexa488 (SA-488), 
BSA-Alexa647 (BSA-647), Dulbecco’s Modified Eagle’s Medium (DMEM), 
phenol red-free DMEM with 25 mmol/l 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid (HEPES), trypsin/ethylenediaminetetraacetic acid, 
and serum were purchased from Fisher Scientific (Loughborough, UK). 
Transferrin-biotin (Tf-Bi), unlabeled recombinant SA, bovine serum albu-
min (BSA), and all other chemicals were purchased from Sigma Aldrich 
(Gillingham, UK) unless otherwise stated.
Generation of Tf-Bi-647. Lyophilized Tf-Bi (5 mg) suspended in 1 ml 
phosphate-buffered saline (PBS) pH 7.4, was added directly to 1 mg 
NHS-Alexa647 (Fisher Scientific) and reacted for 1 hour at room tem-
perature to generate Tf-Bi-647. The conjugate was purified from unreacted 
Alexa647 into PBS pH 7.4 using a G-50 sephadex gel filtration column 
(Life Technologies, Paisley, UK).
Generation of Bi-anti(MHC I)-488. Biotinylated anti-MHC class I anti-
body W6/32 (50 μg in 100 μl; eBioscience, Hatfield, UK) was reacted with 
0.1 mg tetrafluorophenyl-Alexa488 (two vials from a TFP-Alexa488 label-
ing kit; Life Technologies) for 1 hour at room temperature, then purified by 
gel filtration into PBS pH 7.4, as per the kit instructions.
Generation of TRz-Bi-647. TRz formulation (containing 21 mg/ml TRz, 
l-histidine HCl, l-histidine, α,α-trehalose dehydrate, and polysorbate 
20) was kindly donated by the Velindre Cancer Centre (Cardiff, UK). 
This patient TRz formulation (1.5 ml, 32 mg TRz) was buffer exchanged 
into PBS pH 7.4, by sequential use of two 10 ml Zeba Spin desalting col-
umns (Fisher Scientific). From the 1.7 ml of TRz that was eluted, 1.6 ml 
(30 mg) was added directly to 1 mg NHS-Alexa647, and the other 100 μl 
was retained for generation of TRz-488 (see below). NHS-biotin, 1 mg 
(Fisher Scientific) was solubilized in 1 ml of PBS pH 7.4, and 400 μl of this 
was immediately added to the solution of TRz and NHS-Alexa647 (final 
volume 2 ml). The mixture was left to react for 1 hour at room temperature 
without agitation to generate TRz-Bi-647. The conjugate was purified using 
two 10 ml Zeba Spin desalting columns (1 ml sample per column) in PBS 
pH 7.4, then filtered using a 0.2 μm filter (Millipore, Nottingham,  UK).
Generation of TRz-488. TRz, 100 μl in PBS pH 7.4, was reacted with 
0.1 mg tetrafluorophenyl-Alexa488 (two vials from a TFP-Alexa488 label-
ing kit; Life Technologies) for 1 hour at room temperature and then puri-
fied by gel filtration into PBS pH 7.4, as per the kit instructions.
Characterization of conjugated proteins. After purification, conjugated 
proteins were aliquotted into PCR tubes, frozen in liquid nitrogen, and 
stored at −20 °C prior to analysis. UV-visible absorbance spectra were 
obtained using a Jasco V-650 UV-Vis spectrophotometer. Biotin concen-
trations were calculated using a Sensolyte HABA Biotin Quantification Kit 
(Anaspec, Seraing, Belgium).
Cell culture and sources. All cell lines were obtained from ATCC and 
routinely tested for mycoplasma infection. Cell lines were maintained as a 
subconfluent monolayer in complete medium: DMEM supplemented with 
10% (v/v) heat-inactivated fetal calf serum (Gibco, Fisher Scientific). Cells 
were maintained in a humidified 5% CO2 incubator at 37 °C. For live cell 
imaging, cells were seeded onto 35 mm imaging dishes (MatTek, Ashland, 
MA), and for western blotting, cells were seeded into a six-well plate. For 
siRNA transfection studies, 150,000 cells were seeded per dish per well, 
and for all other studies, cells were seeded to 80–90% confluency. HeLa 
cells were left for a minimum of 16 hours to adhere, and SKBR3 and BT474 
cells were left for a minimum of 36 hours to adhere. With the exception of 
incubations performed on ice, all incubations of live cells were performed 
in a humidified 37 °C, 5% CO2 incubator.
Dex-546 labeling of lysosomes. Lysosomes were labeled by pulse-chasing 
with 200 μg/ml of the fluid-phase endocytic probe Dex-546 (ref. 54). For 
this, cells were pulsed with Dex-546 in complete medium, and the probe 
was subsequently chased in dextran-free complete medium. HeLa cells 
were pulsed for 4 hours and chased for 16 hours. SKBR3 and BT474 cells 
were pulsed for 14 hours and chased over the duration of the experiment.
Sequential labeling of HeLa cells with Tf-Bi-647 and SA. HeLa cells were 
incubated for 30 minutes in serum-free medium (phenol red-free DMEM 
pH 7.4, containing 25 mmol/l HEPES, supplemented with 1 mg/ml BSA) 
to allow recycling of serum-derived transferrin. Cells were placed on ice 
for 15 minutes to inhibit endocytosis, incubated with 20 μg/ml Tf-Bi-647 
in ice-cold serum-free medium for 15 minutes and then washed 3× in 
ice-cold PBS pH 7.4. Cells were then incubated with 0 or 1 μg/ml SA in 
ice-cold serum-free medium, and then washed 3× in PBS pH 7.4. Cells 
were finally incubated in pre-warmed imaging medium (phenol red-free 
DMEM pH 7.4, containing 25 mmol/l HEPES supplemented with 10% 
(v/v) heat-inactivated fetal calf serum) and analyzed at the indicated time-
points by live cell confocal microscopy.
Sequential labeling of HeLa cells with Bi-anti(MHC I)-488 or BT474/
SKBR3 cells with TRz-Bi-647. Cells were treated with a total of 50 nmol/l 
antibody in imaging medium for 30 minutes at 37 °C, then washed 3× 
in PBS pH 7.4. This was followed by incubation with 0 or 1 μg/ml SA in 
imaging medium for 1 hour at 37 °C, and then washed 3× with PBS pH 7.4. 
After subsequent incubation in imaging medium for the indicated time 
periods, cells were either imaged by live cell confocal microscopy or were 
lysed for western blotting.
Microscopy. Cells were analyzed on a Leica SP5 confocal laser-scan-
ning microscope equipped with a 488 nm Ar laser, 543/633 nm HeNe 
laser, 63 × 1.4 NA objective utilizing Leica Type F immersion oil. A 
1.5 times zoom was used except where otherwise indicated, produc-
ing a pixel size of 160 × 160 nm through a 95.5 μm pinhole. Alexa488, 
Alexa546, and Alexa647 were excited using 488, 543, and 633 nm lasers, 
respectively. Line-by-line generated images were acquired by simulta-
neous excitation at 488 and 633 nm, followed by excitation at 543 nm 
(15 ms per line). Single slice images of cells were taken ~1 μm above 
the coverslip. For each displayed time point, ≥5 distinct fields of view 
(each containing ~5 cells) were imaged. All microscopy imaging was 
performed on live cells.
Microscopy analysis: colocalization. Within a field of view, cell–cell varia-
tion in the total amount of fluorescence intensity could cause unrepresen-
tatively low PC values. To avoid this, regions of interest from individual 
cells were manually selected using the DIC image as a guide, while ensur-
ing that the selected area was a minimum of 2,000 square pixels. PC values 
were calculated for each cell using the JaCOP ImageJ plugin.68 PC values 
were obtained for ≥8 cells per time point, and the mean values plotted. 
SD, where shown, was calculated for the variation between mean values of 
three independent experiments.
Microscopy analysis: calculation of normalized intensities. A “normalized 
intensity” value was calculated to quantify how the average fluorescence 
intensity per pixel of fluorescent vesicle regions changes over time. Full details 
are provided in Supplementary Method 1. Briefly, an automated script was 
written to detect fluorescent regions and calculate the average fluorescence 
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intensity per pixel in these regions. SD, where shown, was calculated for the 
variation between mean values of three independent experiments.
Microscopy analysis: calculation of normalized intensity in lysosomes. 
The amount of protein delivered to lysosomes was estimated by determin-
ing the amount of labeled protein fluorescence in lysosomal regions, and 
full methodological details are provided in Supplementary Method 2. 
Briefly, fluorescence microscopy images of Dex-546 and labeled protein 
were captured simultaneously; the Dex-546 image was used to identify 
lysosomal regions, and mean protein fluorescence intensity within these 
lysosomal regions was then calculated. SD, where shown, was calculated 
for the variation between mean values of three independent experiments.
siRNA depletion of AP2μ2 in HeLa cells. Cells were transfected with 
100 nmol/l siRNA targeting AP2μ2 (5′-AAGUGGAUGCCUUUCGGGU 
CA-3′) or GFP (5′-GGCUACGUCCAGGAGCGCA-3′) using oligo-
fectamine (Life Technologies) as described previously.69 Experimental 
conditions for achieving and evaluating siRNA depletion are provided 
in Supplementary Methods 3 and 4. siRNA-treated cells were labeled 
with Tf-Bi-647:SA complexes and incubated in imaging medium as 
described above. Cells were washed 3× in ice-cold PBS pH 7.4, before 
incubating with ice-cold acid wash solution (500 mmol/l NaCl, 50 
mmol/l MES (4-morpholineethanesulfonic acid), pH 4.5) for 2 minutes 
to remove surface-bound protein.67 Cells were washed 3× in PBS pH 7.4, 
placed in imaging medium and then immediately analyzed by confocal 
microscopy.
Western blotting. A detailed description for blotting and analysis is given 
in Supplementary Method 5. After blotting onto polyvinylidene fluoride 
membranes, receptors were probed using the following primary anti-
bodies: Her2 (2242; Cell Signaling, Danvers, MA), AP2μ2 (611351; BD 
Bioscience, Oxford, UK), clathrin heavy chain (610499; BD Bioscience), 
glyceraldehyde 3-phosphate dehydrogenase (2118S; Cell Signaling), or 
β-actin (AC-15; Sigma Aldrich). Primary antibodies were detected with 
a corresponding horseradish peroxidase conjugated secondary antibody 
(Fisher Scientific). Horseradish peroxidase was probed using ClarityTM 
Western Enhanced Chemiluminescence substrate (Bio-Rad, Hemel 
Hempsted, UK) and detected using a ChemiDoc XRS system (Bio-Rad).
Statistical analysis. For all statistical analysis, data were obtained from 
three independent experiments (n = 3), and significance values were cal-
culated using a paired Student’s t-test.
SUPPLEMENTARY MATERIAL
Figure S1. Automated calculation of normalized intensity.
Figure S2. UV-visible absorbance spectrum of synthesized protein 
conjugates.
Figure S3. Recycling of Tf-488 and Tf-Bi-647 and cellular retention of 
Tf-Bi-647(:SA) in HeLa cells.
Figure S4. After 10 minutes of internalization, Tf-488 and Tf-Bi-647 
colocalize together, but not with lysosomes.
Figure S5. Depletion of AP2μ2 by siRNA and inhibition of Tf uptake 
in HeLa cells.
Figure S6. Internalization of Bi-anti(MHC I)-488 complexes in HeLa 
cells is dramatically enhanced by addition of SA.
Figure S7. TRz-Bi-647 selectively binds to cells that express Her2.
Figure S8. SA selectively increases delivery of TRz-Bi-647 to lysosomes.
Figure S9. Rate of recovery of Her2 at the plasma membrane, follow-
ing depletion with TRz-Bi-647 and SA.
Table S1. Analysis of UV-visible spectra.
Table S2. Analysis of biotinylation quantiﬁcation.
Supplementary Method 1. Calculation of normalized intensities.
Supplementary Method 2. Calculation of normalized Intensity in 
lysosomes.
Supplementary Method 3. siRNA depletion of AP2μ2 in HeLa cells.
Supplementary Method 4. Evaluation of siRNA depletion of AP2μ2.
Supplementary Method 5. Western blotting and immunodetection.
Supplementary Method 6. Recovery of Her2 at the plasma mem-
brane following depletion with TRz-Bi-647 and SA.
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